PD-1 + VEGF

Class

PD-1 x VEGF bispecific antibody (generic class label — multiple sponsor-specific compounds are registered on CT.gov under this exact intervention text, e.g. ivonescimab/AK112 [Akeso/Summit Therapeutics] and JS207 [Junshi Bioscience])

Pathway

Simultaneous immune-checkpoint blockade and anti-angiogenesis

This mechanism pairs two distinct anticancer strategies in a single bispecific antibody: blockade of PD-1, an immune-checkpoint receptor on T cells, and neutralization of VEGF (vascular endothelial growth factor), a signaling protein that drives blood vessel formation. PD-1 normally dampens T-cell activity when engaged by its ligands, a mechanism tumors exploit to evade immune attack; blocking PD-1 restores the capacity of T cells to recognize and kill malignant cells. VEGF, meanwhile, promotes the disorganized, leaky vasculature characteristic of solid tumors, which also fosters an immunosuppressive microenvironment through poor oxygenation and altered immune-cell trafficking. By engaging both targets, this class aims to restore antitumor immunity while simultaneously normalizing tumor blood vessels, a combination intended to make immune cells more effective once they reach the tumor. Building this dual activity into one bispecific molecule, rather than administering two separate antibodies, reflects a rationale of coordinated, potentially tumor-localized action rather than independent systemic dosing of each blocker. This general approach is relevant across many solid tumor types where both immune evasion and pathological angiogenesis contribute to tumor growth and treatment resistance, and where single-pathway blockade has shown only partial benefit.